Aurobindo Pharma Ltd is navigating market dynamics amid speculation of a potential $5.5 billion acquisition of Prague-based Zentiva, with the company’s stock price fluctuating in response to the uncertainty.

Unfortunately, there is no article text provided.

Aurobindo Pharma’s stock price has declined amid market volatility, but the company’s global presence and diverse product portfolio are expected to help it navigate regulatory changes and industry trends.